EUCTR2010-019874-34-GB进行中（未招募）1 期
A randomised, placebo controlled, double-blind, cross-over trial of the Polypill on risk factor reduction - Polypill Prevention Trial 1 (PPT01)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Participants will be men and women aged 50 years and older, without a history of heart attack or stroke or selection based on other risk factors, for whom there is no medical contra-indication to taking the Polypill.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Ineligibility criteria include:
- •(i) a clinical history of cardiovascular disease
- •(ii) any illness judged to contra-indicate participation in the trial
- •(iii) taking other specified drugs: lithium, cyclosporine or other calcineurin inhibitors, erythromycin or other macrolides, azole antifungals, ritonavir or other protease inhibitors, amiodarone.
研究者
相似试验
终止
3 期
Opioids for breathlessness in people with mesothelioma or asbestosis or other causes of interstitial lung disease.ACTRN12611000711910Flinders University - Department of Palliative and Support Services39
已完成
不适用
Effects of Magnesium supplementation on metabolic control in type 2 diabetic subjectsMetabolic controlMetabolic and Endocrine - DiabetesDiabetesACTRN12613000848707Hospital General de Zona No 46. Instituto Mexicano del Seguro Social100
进行中（未招募）
不适用
A controlled study to look into reducing the number of times a patient suffering from an unexplained cough actually needs to cough by using the investigation medicine XEN-D0501.EUCTR2014-000306-36-GBXention Limited
进行中（未招募）
1 期
A clinical study to determine whether the medical product XEN-D0501 reduces the frequency of coughing in patients with chronic lung disease (chronic obstructive pulmonary disease).Chronic Obstructive Pulmonary Disease.MedDRA version: 17.0Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2013-004041-17-GBXention Limited
进行中（未招募）
不适用
A double-blind, randomised, placebo-controlled, crossover, allergen challenge study, evaluating the safety, tolerability and effects of intranasal administration of recombinant human Clara Cell 10 kDa (rhCC10) protein in subjects with allergic rhinitisEUCTR2006-005420-17-SETB4 Sweden AB